Participated · Equity · Jun 2025

Tadaweb delivers a Small Data Operating System for PAI and OSINT that augments human analysts with AI and a suite of integrated products to reduce time to insight from days to minutes. The SaaS platform ingests PAI, commercially available information, and emerging sources, and integrates with third‑party web tools and APIs. Customers include defence, national security, public safety, cyber threat intelligence and corporate security organisations across Europe and the U.S. Tadaweb emphasises a human‑centric approach, transparency, and a low/no‑code visual query engine to prioritise analyst tradecraft over Big Data automation. The company plans to invest the new capital in product development, hiring top talent, and worldwide go‑to‑market expansion. Founded in 2011, Tadaweb is headquartered in Luxembourg with offices in Paris and London and has now raised additional capital to accelerate growth. Tadaweb builds an OSINT SaaS platform that transforms how businesses generate intelligence from publicly available data. Its platform turns analysts’ manual OSINT tradecraft into repeatable, scalable collection strategies that cut time to insight from days to minutes. The company follows ethical principles by relying only on publicly available information. Founded in 2011 and based in Belval, Luxembourg, Tadaweb employs over 120 people and maintains offices in Paris, London, and Ottawa. The company says the fresh funding will enable it to pursue long-term growth plans worldwide. CEO François Gaspard framed the Wendel partnership as a significant step in that expansion.

Participated · Equity · Dec 2024

Aqemia combines physics-based algorithms and statistical mechanics with generative AI to design novel drug candidates without relying on experimental data. The company is expanding its computational platform to target RNAs, building on work in epitranscriptomics while continuing protein-targeting programs. Aqemia is adapting its platform to handle highly flexible proteins and RNA targets and plans to experimentally determine various RNA and RNA-modifying targets to refine its technology. It reports multiple drug discovery successes across its internal pipeline and collaborations, with its most advanced programs demonstrating efficacy in animal cancer models. A partnered program with Novalix has shown a strong effect on cancer cells and is progressing in vivo models. Aqemia combines quantum-inspired physics, statistical mechanics algorithms and machine learning to train generative AI that designs potential drug molecules. Its approach generates synthetic data to predict molecular properties and interactions, aiming to reduce reliance on costly experimental data. The company’s initial therapeutic focus is oncology and immuno-oncology. Aqemia has an existing multi-year collaboration with Sanofi that could be worth up to $140 million contingent on R&D milestones. With a fresh $38M raise, the company plans to expand hiring and open a London office in early 2025 to access UK talent. This fundraising follows a €30M ($31.5M) raise in January and takes total funding past $100M. AQEMIA operates a proprietary drug discovery platform that combines generative artificial intelligence with quantum and statistical mechanics (deep physics) algorithms to design novel small-molecule candidates. The company reports several drug discovery successes both in its internal pipeline and in collaborations with pharma partners. Its internal pipeline already includes multiple projects being tested in animals, primarily in oncology and immuno-oncology, with plans to expand into the full spectrum of therapeutic areas. AQEMIA intends to scale its GenAI and deep-physics platform, expand its team with top-tier talent, and accelerate its wholly-owned pipeline of projects and assets. Leadership states the company is advancing programs toward clinical trials. The company cites a recent $140 million drug discovery deal with Sanofi as an example of its external collaboration successes. Aqemia has built a technological platform—Aqemia’s Launchpad—that pairs deep physics algorithms with generative AI to design novel drug candidates without relying on prior experimental datasets. The company grew from a spin-off of École Normale Supérieure to a 50-person team in three years and claims its deep-physics algorithms are up to 10,000x faster while maintaining costs and accuracy. Its Launchpad has produced collaborations (disclosed and undisclosed) worth up to millions of euros with major pharma partners including Sanofi, Janssen and Servier. Aqemia has launched a proprietary pipeline of several drug discovery projects spanning in vitro to in vivo stages, with a focus on oncology and immuno-oncology. The firm intends to scale a massive pipeline of wholly owned discovery projects and advance candidates into clinical trials either alone via biotech spin-offs or with partners. The company is actively recruiting to address further technology and drug discovery challenges. Aqemia develops core software, derived from academic research at École normale supérieure (PSL), that predicts the affinity between pharmaceutical targets and molecules in minutes. The company says its method is faster than other software, which can take up to a week, enabling rapid screening of millions of compounds. With a mission to disrupt the $60 billion drug discovery market, Aqemia aims to improve the speed and success rate of identifying drug candidates. The €1 million pre-seed financing led by Elaia will support spinning off the academic lab and recruiting a world-class team. Management includes CEO Maximilien Levesque, Ph.D., and COO Emmanuelle Martiano, who plan to hire in silico drug hunters, a software developer, and experts in generative artificial intelligence. Elaia framed the investment as aligned with its PSL Innovation Fund strategy to back early-stage, disruptive deeptech.

Led · Series C · Jun 2024

YesWeHack operates a bug-bounty and vulnerability management platform that mobilises a community of tens of thousands of ethical hackers to test customers' websites, apps, devices and digital infrastructure. The platform offers integrated, API-based solutions including Bug Bounty, Vulnerability Disclosure Policy, Pentest Management and Attack Surface Management. It serves more than 500 customers across 40 countries, covering CAC 40 firms, telecoms, unicorns and public institutions, with clients such as Louis Vuitton, Tencent and Orange. Since its last funding round in 2021 the company reports a sixfold increase in annual recurring revenue and a tripling of registered ethical hackers. YesWeHack plans to use the new funding to invest in artificial intelligence, launch new solutions and accelerate international expansion. Founded by ethical hackers in 2015 and headquartered in Paris, the company emphasises compliance and a customer-focused technological roadmap. YesWeHack, founded in 2013 and based in Rouen, operates a bug bounty platform that connects more than 7,000 cybersecurity experts across 120 countries with organisations to report vulnerabilities in websites, mobile apps, infrastructure and connected devices. The company offers a pay-per-vulnerability model to help firms remediate security gaps using external ethical hackers. YesWeHack positions its service within the DevSecOps trend, promoting an agile, proactive approach to embedding security into development projects. With CNP Assurance using the YesWeHack platform since July 2018, the company is emphasizing real-world enterprise adoption. The new funding is intended to expand its presence in France and accelerate international development, particularly across Europe and Asia. YesWeHack has also strengthened its strategic capabilities by adding industry figures to its board, including Laurent Seror, Eric Leandri, Charles Beigbeder, and Jonathan Denais.

Participated · Series B · Feb 2023

Brigad operates a platform that lets hospitality businesses post short-term shifts or “missions” and notifies self-employed professionals who meet the requirements and availability. Workers choose missions they want, giving them flexibility and control over shifts; Brigad says roughly 80% of missions are accepted by qualified professionals within two hours. The service is already used by major hospitality venues including the Berkeley Hotel (London), The Ritz, Isabel Mayfair, Mosaic Pubs, Sketch, Nobu, and Big Mamma. The company positions itself as a sector-specific alternative to general job boards, addressing severe staffing shortages in hospitality. Brigad plans to use new funding to further accelerate growth in key European markets. Financially, the startup has just completed a €33 million Series B and, since 2016, has raised north of €50 million in total. Brigad is a French startup that links job candidates with companies for short-term assignments. The company operates a technology-driven matching service that pairs candidate profiles with temporary work offers. It currently focuses on hotels and restaurants and operates only in Paris. Brigad raised €2.2 million from previous investors including accelerator 50 Partners and Square Capital. The startup plans to use the funding to expand across Europe, opening offices in London, Bordeaux, and Barcelona. It also intends to expand into additional sectors such as sales, construction, health, and education. Brigad operates an on-demand staffing marketplace connecting restaurants with temporary workers. The company was one of four startups selected to pitch during Uber's UberPITCH program, which spanned 37 cities and 21 countries. Brigad met with Uber CEO Travis Kalanick and Uber's head of EMEA operations, Pierre-Dimitri Gore-Coty, in Berlin as part of the program. Uber made an undisclosed investment in Brigad alongside three other startups; the company is identified as being based in France. Uber described the investments as unplanned, equal across the four startups, and "relatively small but hopefully transformational." No additional financial or operating metrics were disclosed in the article.